Craig Hallum Increases Eton Pharmaceuticals (NASDAQ:ETON) Price Target to $18.00

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective raised by research analysts at Craig Hallum from $15.00 to $18.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s target price would suggest a potential upside of 49.88% from the stock’s previous close.

Separately, HC Wainwright boosted their price target on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday.

Eton Pharmaceuticals Price Performance

Shares of ETON opened at $12.01 on Wednesday. The company’s fifty day moving average price is $11.64 and its 200-day moving average price is $7.35. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $15.00. The firm has a market capitalization of $312.87 million, a PE ratio of -54.59 and a beta of 1.38.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parkman Healthcare Partners LLC raised its stake in shares of Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after buying an additional 7,029 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals during the third quarter valued at approximately $54,000. Jane Street Group LLC acquired a new position in Eton Pharmaceuticals in the third quarter valued at approximately $90,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in Eton Pharmaceuticals by 86.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock worth $390,000 after purchasing an additional 30,167 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Eton Pharmaceuticals by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock worth $1,637,000 after purchasing an additional 32,365 shares during the period. 27.86% of the stock is currently owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.